
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NMX1
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : National Heart, Lung, And Blood Institute
Deal Size : $2.0 million
Deal Type : Funding
Details : The SBIR grant will support the development of NMX1 and novel small molecules that protect Triple-Negative Breast Cancer (TNBC) patients from the devastating long-term cardiotoxic effects of doxorubicin chemotherapy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 26, 2022
Lead Product(s) : NMX1
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : National Heart, Lung, And Blood Institute
Deal Size : $2.0 million
Deal Type : Funding
